molecules-logo

Journal Browser

Journal Browser

Novel Kinase Inhibitors for the Treatment of Autoimmune and Inflammatory Diseases

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: 30 April 2024 | Viewed by 1892

Special Issue Editor


E-Mail Website
Guest Editor
Institute of Bioorganic Chemistry, Polish Academy of Sciences Z. Noskowskiego St. 12/14, 61-704 Poznań, Poland
Interests: macromolecular crystallography; small molecule crystallography; structural enzymology; protein-ligand interactions; antibiotic resistance; cellular methylation; S-adenosyl-L-homocysteine hydrolase

Special Issue Information

Dear Colleagues,

Non-controlled inflammation response and the dysregulation of the immune system may lead to serious issues related to various pathological processes in humans. Chronic inflammation is directly associated with numerous diseases, including asthma, Crohn’s disease, psoriasis or rheumatoid arthritis. On the other hand, approximately 100 autoimmune diseases, such as multiple sclerosis, type 1 diabetes or some nephropathies, have been described so far. Herein, the inflammation process is activated and, in turn, an individual’s own tissues are damaged due to an autoimmune response. Unsurprisingly, the main therapies against autoimmune and inflammatory diseases target kinases involved in disturbed inflammation processes. Therapeutics approved and used for treating these diseases usually target two types of enzymes: the non-receptor tyrosine protein (TYK2) and Janus (JAK) kinases. However, there has been significant progress in developing new kinase inhibitors, which also target other kinases involved in the inflammatory processes, highlighting the scientific importance of this topic.

The Special Issue aims to collect suitable research articles, communications, reviews or perspective articles related to the title “Novel Kinase Inhibitors for the Treatment of Autoimmune and Inflammatory Diseases” to emphasize the recent advances in the development of inhibitors that target enzymes involved in pathological processes. This Special Issue will focus on, but is not limited to, the biological, chemical, structural and pharmacological aspects related to developing novel immunosuppressants and anti-inflammatory drugs.

Dr. Krzysztof Brzeziński
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • kinase
  • enzyme inhibition
  • drug design
  • organic synthesis
  • structural biology
  • medicinal chemistry
  • structure-activity relationship
  • enzyme–ligand complex

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

20 pages, 1751 KiB  
Review
Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
by Izabella Ryguła, Wojciech Pikiewicz and Konrad Kaminiów
Molecules 2023, 28(24), 8064; https://doi.org/10.3390/molecules28248064 - 13 Dec 2023
Cited by 1 | Viewed by 1414
Abstract
Janus kinase inhibitors, also known as JAK inhibitors, JAKinibs or JAKi, are a new group of disease-modifying drugs. They work by inhibiting enzymes involved in the transmission of information from receptors located in the cell membrane to the cell interior, specifically to the [...] Read more.
Janus kinase inhibitors, also known as JAK inhibitors, JAKinibs or JAKi, are a new group of disease-modifying drugs. They work by inhibiting enzymes involved in the transmission of information from receptors located in the cell membrane to the cell interior, specifically to the cell nucleus, thus disrupting the JAK-STAT pathway. This pathway plays a role in key cellular processes such as the immune response and cell growth. This feature is used in the treatment of patients with rheumatological, gastroenterological and hematological diseases. Recently, it has been discovered that JAK-STAT pathway inhibitors also show therapeutic potential against dermatological diseases such as atopic dermatitis, psoriasis, alopecia areata and acquired vitiligo. Studies are underway to use them in the treatment of several other dermatoses. Janus kinase inhibitors represent a promising class of drugs for the treatment of skin diseases refractory to conventional therapy. The purpose of this review is to summarize the latest knowledge on the use of JAKi in dermatological treatment. Full article
Show Figures

Figure 1

Back to TopTop